Investigating how malondialdehyde affects blood vessel health in atherosclerosis
Malondialdehyde-induced Endothelial Dysfunction in Atherosclerosis
This study is looking at how a substance called malondialdehyde (MDA) can harm blood vessels and lead to heart problems, and it’s testing whether a special antibody can help protect against this damage, which could lead to better ways to prevent or treat heart disease for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10687848 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of malondialdehyde (MDA), a byproduct of fat breakdown, in causing damage to the inner lining of blood vessels, which is crucial in the development of atherosclerosis. The study uses genetically modified mice that produce an antibody targeting MDA to explore how neutralizing this compound can reduce atherosclerosis. By examining the effects of MDA on endothelial cells, the research aims to uncover the underlying mechanisms that contribute to vascular health and disease. Patients may benefit from insights gained about how to prevent or treat conditions related to atherosclerosis and cardiovascular diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for atherosclerosis, including those with cardiovascular disease or metabolic disorders.
Not a fit: Patients with conditions unrelated to atherosclerosis or those who do not have risk factors for cardiovascular disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating atherosclerosis and related cardiovascular diseases.
How similar studies have performed: Previous research has shown promising results in targeting similar inflammatory processes in cardiovascular diseases, suggesting potential for success in this approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Sun, Xiaoli — University of Texas Hlth Science Center
- Study coordinator: Sun, Xiaoli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.